Newsletter Tool

PM Tracker

Today’s Big News

Jun 25, 2025

New-look ACIP, down a member and homing in on ‘long-settled safety topics,’ kicks off controversial vaccine meeting

Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs

Uptake of Gilead's Yeztugo will be swift, analyst says after discussion with HIV doc

Kymera suffers Sanofi setback but secures $750M Gilead deal

FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys

Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma

FDA moves to block Olympus endoscope imports over manufacturing issues

Featured

New-look ACIP, down a member and homing in on ‘long-settled safety topics,’ kicks off controversial vaccine meeting

By Fraiser Kansteiner

With controversial presentation topics on the docket and the already abbreviated panel suddenly down one member, this week’s meeting of the CDC’s Advisory Committee on Immunization Practices (ACIP) is shaping up to be a long, strange two days.

Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs

By James Waldron

Bayer-owned BlueRock Therapeutics is laying off 50 employees and shuttering its research labs in Cambridge, Mass., in order to focus its resources on its priority cell therapies, a spokesperson said.

Uptake of Gilead's Yeztugo will be swift, analyst says after discussion with HIV doc

By Kevin Dunleavy

What kind of uptake can Gilead expect for its long-acting HIV prophylactic injection Yeztugo, which was approved last week by the FDA? A HIV physician, who shared her views with analysts from Mizuho Securities, expects that a “majority” of her 125 pre-exposure prophylaxis (PrEP) users will switch to Yeztugo within the next 12 months, according to an investor note recapping the discussion.

Kymera suffers Sanofi setback but secures $750M Gilead deal

By Nick Paul Taylor

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 million deal with Gilead.

FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys

By Angus Liu

In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, the agency is investigating two Duchenne muscular dystrophy patient deaths following treatment with Sarepta Therapeutics’ Elevidys.

Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma

By James Waldron

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still struggling to sit independently despite having received Novartis’ Zolgensma.

FDA moves to block Olympus endoscope imports over manufacturing issues

By Conor Hale

The FDA is shutting the door to imports of certain endoscope hardware manufactured by Olympus, saying that a production site in Japan has failed to meet quality requirements.

J&J launches AI surgery funding competition with Nvidia, AWS

By Conor Hale

Johnson & Johnson has teamed up with Nvidia and Amazon Web Services to make AI an integral tool in the OR.

Novo Nordisk questioned over controversial Spanish obesity awareness campaign

By Nick Paul Taylor

Novo Nordisk is under fire over a Spanish obesity awareness campaign. After the campaign stirred up controversy, the Spanish ministry of health wrote to the drugmaker about a possible violation of drug advertising regulations.